Abdullahi v. Pfizer, Inc.

¶1SUMMARY ORDER

¶2AFTER ARGUMENT AND UPON DUE CONSIDERATION, IT IS HEREBY ORDERED, ADJUDGED AND DECREED that the judgment of the District Court is hereby VACATED and the case REMANDED.

¶3Plaintiffs Rabi Abdullahi et al. appeal from an order and final judgment entered September 26, 2002 by the United States District Court for the Southern District of New York (William H. Pauley, Judge), dismissing their complaint on grounds of forum non conveniens. Defendant Pfizer, Inc. cross-appeals from the District Court’s contemporaneous denial of Pfizer’s motion to dismiss pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure.

¶4Plaintiffs are minors and their guardians, all of whom reside in Nigeria. De*51fendant Pfizer, the world’s largest pharmaceutical corporation, was incorporated in Delaware and has its headquarters in New York. The central events at issue in this lawsuit occurred in 1996, not long after epidemics of bacterial meningitis, measles and cholera broke out in Kano, Nigeria. Pfizer established a treatment center at the Infectious Disease Hospital in Kano to treat victims of the meningitis epidemic. Plaintiffs allege that Pfizer, instead of using safe and effective bacterial meningitis treatments, used the epidemic as an opportunity to conduct biomedical research experiments on Nigerian children involving Pfizer’s “new, untested and unproven” antibiotic, trovaflozacin mesylate, better known by its brand name, Trovan®. Abdullahi v. Pfizer, No. 01 Civ. 8118, 2002 WL 31082956, at *1 (S.D.N.Y. Sept. 17, 2002).1 Plaintiffs claim that Pfizer failed to explain to the children’s parents that the proposed treatment was experimental, that they could refuse it, or that other organizations offered more conventional treatments at the same site free of charge. Id. at *2. In addition, plaintiffs assert that half of the children who participated in Pfizer’s treatment program were deliberately given inadequate doses of ceftriaxone-an FDA-approved drug shown to be effective in treating meningitis-so that Trovan would look more effective by comparison. Id. According to plaintiffs, five of the children who received Trovan and six of the children who were “low-dosed” with ceftriaxone died and others treated by Pfizer suffered very serious injuries, including paralysis, deafness and blindness. Id.

¶5Plaintiffs filed their complaint in this action on August 29, 2001. They asserted that one of the bases of jurisdiction in the District Court was 28 U.S.C. § 1350, the Alien Tort Claims Act (“ATCA”), because Pfizer purportedly violated the Nuremberg Code, the Declaration of Helsinki, article 7 of the International Covenant on Civil and Political Rights, FDA regulations and other norms of international law. In a Memorandum and Order dated September 16, 2002, the District Court (William H. Pauley, Judge) denied Pfizer’s 12(b)(6) motion to dismiss the complaint for failure to state a claim under the ATCA but granted Pfizer’s motion to dismiss the complaint on forum non conveniens grounds. See Abdullahi, 2002 WL 31082956, at *6, *12. Judgment was entered on September 26, 2002 and this timely appeal followed.

¶6We review a forum non conveniens dismissal for “a clear abuse of discretion.” Monegasque De Reassurances S.A.M. v. Nak Naftogaz of Ukr., 311 F.3d 488, 498 (2d Cir.2002). In evaluating the forum non conveniens question, the District Court properly considered: (i) the level of deference owed to the plaintiffs; (ii) the availability of an adequate alternative forum; and (iii) whether the public and private interest factors weigh in favor of an adjudication in the plaintiffs’ chosen forum or in the defendant’s proposed alternative. See id. at 500. The District Court resolved each of these questions in Pfizer’s favor, finding that: (i) plaintiffs’ choice of forum was owed “less deference” because they are foreign plaintiffs; (ii) Nigeria was an adequate alternative forum; and (iii) the public and private interest factors favored a trial in Nigeria over one in New York. Abdullahi, 2002 WL 31082956, at *6-12.

¶7Our principal problem in resolving this appeal on the current record relates to the inquiry into the existence of an adequate *52alternative forum. It is well settled that a forum non conveniens motion “may not be granted unless an adequate alternative forum exists,” and, in general, “[a]n alternative forum is ordinarily adequate if the defendants are amenable to service of process there and the forum permits litigation of the subject matter of the dispute.” Monegasque, 311 F.3d at 499 (quoting Piper Aircraft Co. v. Reyno, 454 U.S. 235, 254 n. 22, 102 S.Ct. 252, 70 L.Ed.2d 419 (1981)). To satisfy this element of the analysis, Pfizer demonstrated that it was subject to service of process in Nigeria and that Nigerian law provided an adequate remedy for plaintiffs’ claims because it recognizes negligence, medical malpractice, and personal injury claims. Abdullahi 2002 WL 31082956, at *7.

¶8In “rare” cases, however, as the District Court aptly observed, “if the plaintiff shows that conditions in the foreign forum plainly demonstrate that ‘plaintiffs are highly unlikely to obtain basic justice therein,’ ” a defendant’s forum non conveniens motion must be denied. Id. at *8 (citation omitted). In this case, the plaintiffs made just such a claim-arguing vehemently that the Nigerian court system was too corrupt to be considered an adequate alternative forum. In support of these allegations, plaintiffs submitted to the District Court affidavits and a number of State Department and United Nations’ reports that included general observations about the corruption in Nigeria’s judiciary. See id. Although it observed that “the record offered by plaintiffs indicates that Nigeria is a nation experiencing difficulties in its transition from a dictatorship to a democracy,” the District Court declined to find Nigeria to be an inadequate alternative. According to the District Court, “nothing in plaintiffs’ submissions reaches beyond the most general of characterizations,” and “conclusory allegations of corruption or bias on the part of the foreign forum will not prevent a dismissal on forum non conveniens grounds.” Id. at *8-9.

¶9On appeal, the plaintiffs have made a motion that we take judicial notice of the fact that “[a] parallel action filed in Nigeria [Zango v. Pfizer, No. FHC/ K/CS/204/2001], involving different plaintiffs but the same course of conduct by Pfizer, was dismissed on August 19, 2002.”2 Plaintiffs request that we notice both the fact of the dismissal “and the reasons for it.” Plaintiffs rely on the statements included in the Notice of Discontinuance as proof of the Zango plaintiffs’ reasons for discontinuing the action. (The notice blames an indefinite adjournment and the fact that the judge hearing the case declined jurisdiction “for personal reasons.”)

¶10Pfizer objects to the plaintiffs’ motion and requests, instead, that we take notice of the entire Zango docket, minutes and rulings because, according to Pfizer, these entries, minutes and rulings show that the Zango plaintiffs’ version of events (as outlined in the Notice of Discontinuance) is disingenuous. Plaintiffs oppose Pfizer’s motion, arguing that we “cannot fully understand the significance of the events in Zango on the [selective] record provided by Pfizer.”

¶11The plaintiffs’ understanding of the Zango events conflicts with the interpreta*53tion that Pfizer wishes us to draw from the docket entries (which were not presented to the District Court) and this dispute is impossible for us to resolve based on the record before us. As such, this would be an inappropriate fact for judicial notice.3See Fed.R.Evid. 201(b) (“A judicially noticed fact must be one not subject to reasonable dispute in that it is either (1) generally known within the territorial jurisdiction of the trial court or (2) capable of accurate and ready determination by resort to sources whose accuracy cannot reasonably be questioned.”); see also Weinstein’s Federal Evidence § 201.13[l][b] (“Courts will not take judicial notice of factual propositions that are subject to reasonable dispute, even if they appear as allegations in pleadings, trial testimony, or findings of fact in judgments.”) (footnotes omitted). These facts, however, would seem to be relevant to the foru/rn non conveniens analysis—perhaps providing just the type of specific information that the District Court found lacking. As such, we remand the case to the District Court for proceedings to determine what precipitated the dismissal in Zango and to evaluate whether that impacts the District Court’s forum non conveniens analysis.

¶12We also note that while this appeal was pending, another panel of this Court decided Flores v. Southern Peru Copper Corp., No. 02-9008, 2003 WL 22038598 (2d Cir. Aug.29, 2003) (holding that plaintiffs’ claims of local, intranational environmental pollution were not actionable under the ATCA because such pollution does not violate customary international law). The applicability of Floresto the instant case is not entirely clear, in large part because this issue—whether the conduct alleged qualifies as a violation of “customary international law” under the ATCA—is one that Pfizer did not address before the District Court.4 Both parties have glossed over the issue on appeal.

¶13Because we are remanding for further proceedings with respect to Pfizer’s motion to dismiss on forum non conveniens grounds, we do not reach the subject of Pfizer’s cross appeal—the propriety of the District Court’s denial of Pfizer’s Rule 12(b)(6) motion.

¶14For the foregoing reasons, we VACATE the District Court’s judgment granting Pfizer’s motion to dismiss on forum non conveniens grounds and REMAND the matter for further proceedings not inconsistent with this summary order.